6-bromo-8-methyl-4(1H)-quinazolinone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 6-bromo-8-methyl-4(1H)-quinazolinone
• 英文别名: 6-bromo-8-methylquinazolin-4(3H)-one；6-bromo-8-methyl-3H-quinazolin-4-one
• 化学式: C₉H₇BrN₂O
• 分子量: 239.071
• InChiKey: NZLQEKSZZSIZBS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-bromo-8-methyl-4(1H)-quinazolinone 在 potassium phosphate 、 tris-(dibenzylideneacetone)dipalladium(0) 、 氯化亚砜 、 氢溴酸 、 N,N-二异丙基乙胺 、 N,N-二甲基甲酰胺 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 N,N-二甲基乙酰胺 、 溶剂黄146 、 甲苯 为溶剂， 反应 15.0h， 生成 1-({2-[6-(3,3-difluoropyrrolidin-1-yl)-8-methylquinazolin-4-yl]-1,2,3,4-tetrahydroisoquinolin-7-yl}carbonyl)piperidin-4-amine
  参考文献：
  名称：

  [EN] QUINAZOLINE INHIBITORS OF PI3K
  [FR] INHIBITEURS QUINAZOLINES DE PI3K

  摘要：

  公开号：

  WO2014160177A3
• 作为产物：
  描述：

  2-氨基-5-溴-3-甲基苯甲酸 在 硫酸 作用下， 以 formamide 为溶剂， 反应 84.0h， 生成 6-bromo-8-methyl-4(1H)-quinazolinone
  参考文献：
  名称：

  [EN] QUINAZOLINE INHIBITORS OF PI3K
  [FR] INHIBITEURS QUINAZOLINES DE PI3K

  摘要：

  公开号：

  WO2014160177A3

文献信息

• Synthesis and Anticoccidial Activities of Novel N-(2-Aminophenyl)-2-quinazolinone-acetamide Hydrochloride
  作者：Chun-Rong Yan、Li Yang、A-Rong Guo、Kui Nie、Yu-Liang Wang

  DOI：10.14233/ajchem.2013.14162

  日期：——

  Eight novel N-(2-aminophenyl)-2-quinazolinone-acetamide hydrochloride were synthesized and their structures were identified by 1H NMR, MS and IR spectra. Seven of the new compounds were chosen for anticoccidial activity test and the results showed that N-(2-aminophenyl)-2-(6-methyl-8-bromo quinazolinone)acetamide hydrochloride (3h) exhibited anticoccidial activity against Eimeria tenella in the chicken diet with a dose of 18 mg/Kg.

  合成了八种新型N-(2-氨基苯基)-2-喹嗪啉酮-乙酰胺盐酸盐，并通过1H NMR、MS和IR光谱确认了其结构。挑选了七种新化合物进行抗球虫活性测试，结果显示N-(2-氨基苯基)-2-(6-甲基-8-溴喹嗪啉酮)乙酰胺盐酸盐（3h）在鸡饲料中对小球虫（Eimeria tenella）表现出抗球虫活性，剂量为18 mg/Kg。
• DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST
  申请人：Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

  公开号：EP3666772A1

  公开（公告）日：2020-06-17

  The present application belongs to the field of medicine. In particular, the present application relates to a diarylthiohydantoin compound as an androgen receptor antagonist or a pharmaceutically acceptable salt thereof, a preparation method of the same, a pharmaceutical composition comprising the compound, and a use thereof in treating a cell proliferative disease mediated by androgen. The compound of the present application has good antagonistic effect on androgen receptor and exhibits excellent antitumor effect.

  本申请属于医药领域。具体而言，本申请涉及一种作为雄激素受体拮抗剂的二芳基硫代海因化合物或其药学上可接受的盐、其制备方法、包含该化合物的药物组合物以及其在治疗由雄激素介导的细胞增殖性疾病中的用途。本申请的化合物对雄激素受体具有良好的拮抗作用，并表现出优异的抗肿瘤效果。
• Discovery, Synthesis, and Biological Evaluation of Thiazoloquin(az)olin(on)es as Potent CD38 Inhibitors
  作者：Curt D. Haffner、J. David Becherer、Eric E. Boros、Rodolfo Cadilla、Tiffany Carpenter、David Cowan、David N. Deaton、Yu Guo、Wallace Harrington、Brad R. Henke、Michael R. Jeune、Istvan Kaldor、Naphtali Milliken、Kim G. Petrov、Frank Preugschat、Christie Schulte、Barry G. Shearer、Todd Shearer、Terrence L. Smalley、Eugene L. Stewart、J. Darren Stuart、John C. Ulrich

  DOI：10.1021/jm502009h

  日期：2015.4.23

  A series of thiazoloquin(az)olinones were synthesized and found to have potent inhibitory activity against CD38. Several of these compounds were also shown to have good pharmacokinetic properties and demonstrated the ability to elevate NAD levels in plasma, liver, and muscle tissue. In particular, compound 78c was given to diet induced obese (DIO) C57Bl6 mice, elevating NAD > 5-fold in liver and >1.2-fold in muscle versus control animals at a 2 h time point. The compounds described herein possess the most potent CD38 inhibitory activity of any small molecules described in the literature to date. The inhibitors should allow for a more detailed assessment of how NAD elevation via CD38 inhibition affects physiology in NAD deficient states.
• [EN] SUBSTITUTED QUINAZOLINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4<br/>[FR] DÉRIVÉS DE QUINAZOLINONE SUBSTITUÉS ET LEUR UTILISATION EN TANT QUE MODULATEURS ALLOSTÉRIQUES POSITIFS DE MGLUR4
  申请人：DOMAIN THERAPEUTICS

  公开号：WO2020021064A1

  公开（公告）日：2020-01-30

  The present invention relates to novel quinazolinone derivatives of formula (I) as well as pharmaceutical compositions containing these compounds. The compounds of formula (I) as provided herein can act as positive allosteric modulators of metabotropic glutamate receptor subtype 4 (mGluR4), and can thus be used as therapeutic agents, particularly in the treatment or prevention of conditions associated with altered glutamatergic signalling and/or functions or conditions which can be affected by alteration of glutamate level or signalling.
• [EN] QUINAZOLINE INHIBITORS OF PI3K<br/>[FR] INHIBITEURS QUINAZOLINES DE PI3K
  申请人：EXELIXIS INC

  公开号：WO2014160177A3

  公开（公告）日：2015-05-14